MRNA Moderna Inc

$MRNA I’ve figured it out! Basically do the opposite of what everyone on Stocktwits advises!

$MRNA $SLS Now if you are long/Short and still waiting for the 80Th event after 5.6 months you are about to get a surprise of a life time. Let me explain: Read the GPS Regal Pivotal Registrational Phase 3 IA. GPS 80% Immune Response rate= 50 Patients. Dr. Stergiou: GPS Patients that show immune response = Cancer Dormant = Cancer Curative. Where are we stuck at 48? 49?= Functionally Cured. Dr. Stergiou: GPS induces a specific T-cell response in nearly all patients. Data suggests that patients who mount a strong immune response may achieve significantly prolonged remission, effectively keeping the leukemia "dormant" via immune surveillance. Dr. Stergiou: We are moving toward a world where we can hopefully treat the fundamental biology of AML. Our mission is to move past "managing" the disease and toward potentially establishing curative outcomes as the standard of care-preserving the "building" while eliminating the threat for good. Both Scenarios = Shorts GME all over again. 👋🏿 ✌️🙏❤️‍🩹

$MRNA $SLS Honestly, predicting a drop below $8 based on hypothetical negative news about Moderna is speculation, not analysis. GPS is a WT1-targeting peptide immunotherapy, while mRNA vaccines use a different technology. One company’s results cannot simply be applied to another. SELLAS has two distinct value drivers: GPS, approaching the decisive REGAL Phase 3 readout, and SLS009, a CDK9 inhibitor with potential beyond AML. Nobody can guarantee the outcome, but throwing out scary price targets without solid evidence only creates fear in a community waiting for a major catalyst. We deserve facts, science and honest debate, not fear-driven predictions. Challenge the data, question the assumptions, but don’t confuse fear with research. FUD is not DD. Investors deserve better.

$MRNA $SLS I am personally ready for the best chapters that are still to be written with GPS and SLS009. Thank you to everyone who has been part of this journey. ✌️🙏❤️‍🩹

$MRNA $SLS Fair enough, everyone is entitled to an opinion. But adding JMHO, DYOR and NFA doesn’t change the substance of the message. You still chose to link hypothetical negative news about Moderna to a specific $SLS price target below $8. My point is simple: GPS and mRNA vaccines are different technologies, and fear-based price predictions without supporting evidence can mislead investors. Speculation is fine. Presenting it in a way that fuels fear is another matter. Let’s keep the discussion focused on facts, science and the actual REGAL data.

$MRNA Where will the naked shorts buy 1.43 BILLION shares back when this goes 🚀🚀??? .. it could really go parabolic as I see the float is about 4X sold short with naked synthetic shares

$MRNA $SLS 7 trading days left to $SLS GPS Regal Pivotal Registrational Phase 3 study ASH 2026 LBA submission. Very Promising Chapter in $SLS history will begin starting tomorrow Tuesday 10/20/26. ✌️🙏❤️‍🩹

$MRNA kids got excited for the fake pump at the first 15 minutes. Now watch how Wall Street will dump it for months to go lol

$MRNA $MRK Today was the first sign that the market is starting to see Moderna for what it is: not a defensive stock or an established Big Pharma company generating substantial, sustainable profits, but a biotech currently losing around $2 billion a year. It’s in the same league as $SLS and $VKTX, both down about 10%, not Eli Lilly or Merck, which were up today. I’m still waiting for Moderna’s own valuation correction. It’s difficult to justify its current valuation when compared not with its financial performance and profitability, but also it's pipeline and how hard and expense it is to cure cancer. The next two weeks, with next 10 years of valuation expectations baked-in, major “sell the news” catalysts potentially triggering a long-overdue correction. #mindthevaluation

$MRNA $SLS JMHO means JUST MY HUMBLE OPINION. DYOR means DO YOUR OWN RESEARCH. NFA means NOT FINANCIAL ADVICE. -These combined acronyms are obviously Synonymous with speculation, ANALYSIS was never my INTENT.

$MRNA just market makers pumping the price up before Saturdays “it was priced in.” See you under 100 next week Meantime buy $SLS

$MRNA if I wasn’t locked into a poorly timed short here, I’d be all over this thing—both ways. It’s the most predictable, ridiculous, ape-level meme nonsense I’ve ever seen and I’m truly sad that I fucked this one up!

$MRNA not much runway left.... ER is end of it, in just a few days. Selling might start before that...

$MRNA still going strong Also for those who like bottom fishing and technicals $RIVN has the same setup (most importantly a multi year consolidation) that mrna did when I was grabbing this for dirt cheap at $24-25 $SPY $QQQ $SPCX

$MRNA shorts are just guessing every move at this point. positive gamma all the way to 250

$MRNA Moderna is rated Sell as the stock price far exceeds even the most bullish fair value estimates, demanding Keytruda-scale success from intismeran. MRNA's valuation implies $69B in peak sales for intismeran, despite the company only owning half, and first approval is unlikely before 2027. The market is pricing in a perfect outcome, yet the pivotal Phase 3 hazard ratio and broader oncology data remain undisclosed. Moderna's vaccine business continues to burn cash, with consensus and probability-weighted models supporting a value closer to $110 per share.

$MRNA $MRK Same drug. 50/50 profit split. Opposite valuations. Moderna’s cancer-vaccine story is shared 50/50 with Merck. Merck co-develops it, splits the costs and splits the profits. Interestingly, Merck doesn’t get the same benefit. On Aug 19, when the Phase 3 melanoma data came out, both stocks added roughly the same value, about $42–44B each. Since then: 📉 Merck: −$21B, half of that gain gone 📈 Moderna: +$21B, almost 50% more on top That’s a $42B gap between the two halves of the same drug. If the vaccine is worth $65B+ to Moderna, why is the market giving Merck, the partner with the same stake, close to nothing for it? Cleanest way to play the sell the news event for the weekend: Long $MRK Short $MRNA

$MRNA NOV20 225C · update Called at $218 today at 05:10 CT, now $226.89 (+4.08%). The trade is working, with objectives at $231, then $242, and the invalidation at $209. P.S. Watch the push toward $231 from here, because that first objective is close now and how price acts there will tell the story.

$MRNA amazing how so many people get this wrong. Bearish sentiment on such a bullish stock. The bears are the same people that think $IREN $CRWV and $ASTS are good buys right now. To quote Marty charging, you ride the trend till it bends at the end.

$MRNA If Moderna and $MRK unexpectedly reveal compelling evidence that the personalized vaccine works across lung, kidney, bladder or other solid tumors prior to full readout on Saturday investors could start valuing V940 as a platform rather than a single melanoma product. A scenario that could squeeze $300+ quick